Combined modality therapy for small cell lung cancer patient with limited stage disease.
- Author:
Hui-Jie WANG
1
;
Ke-Lin SUN
;
Xiang-Ru ZHANG
;
Yan SUN
;
Yuan-Kai SHI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Lung Neoplasms; pathology; therapy; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; methods; Radiotherapy, Adjuvant; Retrospective Studies; Small Cell Lung Carcinoma; pathology; therapy; Survival Rate
- From: Chinese Journal of Oncology 2007;29(9):701-703
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the efficacy of combined modality therapy for small cell lung cancer (SCLC) patient with limited stage disease (LD).
METHODSThe data of 122 SCLC patients with limited stage disease treated by surgery combined with chemotherapy and radiotherapy were analysed retrospectively.
RESULTSThe median survival time (MST) of the 122 patients was 38 months, the 1-, 3-, 5-year survival rate was 83.6%, 50.0% and 38.0%, respectively. If stratified the patients by TNM stage, the MST of stage I was not reached yet, it was 52 months for stage II and 22 months for stage III (P = 0.001); the 5-year survival rate was 57.1%, 43.1% and 28.3%, respectively. For stage III, the MST and 5-year survival rate was 40 months and 45.3% for the patients who received postoperative chemoradiotherapy, and only 20 months and 26.1% for those who were treated with postoperative chemotherapy alone (P = 0.071).
CONCLUSIONCombined modality therapy can improve the survival of small cell lung cancer patient with limited stage disease, and TNM stage is still a significant prognostic factor.
